The data available in the ARK Portal would not be possible without the participation of research volunteers and the contribution of data by collaborating researchers. Data are made available as Registered or Controlled Access, where individual-level human subject data is Controlled Access and can not be redistributed. Access to any data requires the registration of a Synapse account and agreement to the Synapse Terms and Conditions of Use, and the .
Attributions and Acknowledgments
All data use must be acknowledged in publications. Acknowledgment statements will vary by ARK Portal Program. You agree to this through the Clickwrap terms included as part of the ARK data access request process.
AMP® RA/SLE
"The results published here are in whole or in part based on data obtained from the ARK Portal ( https://arkportal.synapse.org/ ). This work was supported by the Accelerating Medicines Partnership® Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Program. AMP® is a public-private partnership (AbbVie Inc., Arthritis Foundation, Bristol-Myers Squibb Company, Foundation for the National Institutes of Health, GlaxoSmithKline, Janssen Research and Development, LLC, Lupus Foundation of America, Lupus Research Alliance, Merck & Co., Inc., National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Pfizer Inc., Rheumatology Research Foundation, Sanofi and Takeda Pharmaceuticals International, Inc.) created to develop new ways of identifying and validating promising biological targets for diagnostics and drug development Funding was provided through grants from the National Institutes of Health (UH2-AR067676, UH2-AR067677, UH2-AR067679, UH2-AR067681, UH2-AR067685, UH2- AR067688, UH2-AR067689, UH2-AR067690, UH2-AR067691, UH2-AR067694, and UM2- AR067678)."
AMP® AIM
“The results published here are in whole or in part, based on data obtained from the ARK Portal (https://arkportal.synapse.org/ ). This research received support from the Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) Program dedicated to better understanding the molecular and cellular drivers of autoimmune diseases and inflammation. AMP® AIM is managed by the Foundation for the NIH (FNIH) supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute of Allergy and Infectious Diseases (NIAID), the National Eye Institute (NEI), and the NIH Office of Research on Women’s Health (ORWH). Collaborative private sector partners include AbbVie Inc., Arthritis Foundation, Autoimmune Association, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Research and Development, LLC, Lupus Foundation of America, Lupus Research Alliance, Merck Pharmaceutical, Inc., National Psoriasis Foundation, National Scleroderma Foundation, Novartis Pharma AG, Pfizer Inc., Sanofi, Sjögren's Foundation, Scleroderma Research Foundation, UCB, and Vistera. Financial support was provided by the following National Institutes of Health grants: UC2-AR081025, UC2-DE032254, UC2-AR081029, UC2-AR081039, UC2-AR081023, UC2-AR081031, UC2-AR081032, UC2-AR081033, and UC2-AR081034.”
UMass V-CoRT
"The results published here are in whole or in part based on data obtained from the ARK Portal (https://arkportal.synapse.org/) contributed by Dr. Manuel Garber and John Harris (University of Massachusetts) from <dataset DOI> as described in publication <publication DOI>. The data generation was funded by NIH grant 5P50AR080593 and NIAID grant 5U01AI176310."
Please be sure to cite both the associated publication DOI and dataset DOI.